查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
循环肿瘤细胞市场:世界的市场机会分析及产业预测，2020-2030年市场
市场调查报告书
商品编码
1147375

循环肿瘤细胞市场:世界的市场机会分析及产业预测，2020-2030年市场

Circulating Tumor Cell Market: Global Opportunity Analysis and Industry Forecast, 2020-2030 Market
出版日期: | 出版商: Allied Market Research | 英文 | 商品交期: 2-3个工作天内

价格
简介目录

循环肿瘤细胞检验，能查出癌症患者血液中的癌细胞，并定量化。

CTC中存在各种生物学表型，包括上皮、间充质、干细胞和混合细胞。这些细胞在血液中的含量非常少，而且数量远少于其他细胞(尤其是白细胞)。因此，CTC的检测需要分离/浓缩步骤和第二检测步骤。循环肿瘤细胞在诊断前、治疗前以及治疗中和治疗后的许多潜在应用为参与循环肿瘤细胞 (CTC) 浓缩和分离产品开发的参与者提供了有利的成长机会。

目录

第1章 简介

第2章 摘要整理

第3章 市场情势

  • 市场定义和范围
  • 主要的调查结果
    • 最高层的投资处
    • 主要的成功策略
  • 波特的五力分析
    • 供给企业谈判力
    • 新加入业者的威胁
    • 替代品的威胁
    • 竞争企业间的敌对关係
    • 买方议价能力
  • 市场情况分析/龙头企业定位
    • 2021年市场占有率分析/龙头企业定位
  • 市场动态
    • 促进因素
    • 阻碍因素
    • 机会
  • COVID-19影响分析

第4章 循环肿瘤细胞市场:各技术

  • 市场概要
    • 市场规模、预测:各技术
  • CTC检测浓缩方法
    • 主要的市场趋势，成长要素，机会
    • 市场规模、预测:各地区
    • 市场占有率分析:各国
  • CTC直接检测法
    • 主要的市场趋势，成长要素，机会
    • 市场规模、预测:各地区
    • 市场占有率分析:各国
  • CTC分析
    • 主要的市场趋势，成长要素，机会
    • 市场规模、预测:各地区
    • 市场占有率分析:各国

第5章 循环肿瘤细胞市场:各应用领域

  • 市场概要
    • 市场规模、预测:各应用领域
  • 临床/液态切片
    • 主要的市场趋势，成长要素，机会
    • 市场规模、预测:各地区
    • 市场占有率分析:各国
    • 风险评估
      • 市场规模及预测
    • 筛检和监测
      • 市场规模与预测
  • 调查
    • 主要的市场趋势，成长要素，机会等
    • 市场规模、预测:各地区
    • 市场占有率分析:各国
    • 癌症干细胞的肿瘤形成研究
      • 市场规模、预测
    • 医药品/开发治疗
      • 市场规模、预测

第6章 循环肿瘤细胞市场:各终端用户

  • 市场概要
    • 市场规模、预测:各终端用户
  • 医院诊所
    • 主要的市场趋势，成长要素，机会
    • 市场规模、预测:各地区
    • 市场占有率分析:各国
  • 研究学术机构
    • 主要的市场趋势，成长要素，机会
    • 市场规模、预测:各地区
    • 市场占有率分析:各国
  • 诊断中心
    • 主要的市场趋势，成长要素，机会
    • 市场规模、预测:各地区
    • 市场占有率分析:各国

第7章 循环肿瘤细胞市场:各地区

  • 市场概要
    • 市场规模、预测:各地区
  • 北美
    • 主要市场趋势与商机
    • 市场规模、预测:各技术
    • 市场规模、预测:各应用领域
    • 市场规模、预测:各终端用户
    • 市场规模、预测:各国
    • 美国的循环肿瘤细胞市场
      • 市场规模及预测:各技术
      • 市场规模及预测:各应用领域
      • 市场规模及预测:各终端用户
    • 加拿大循环肿瘤细胞市场
      • 市场规模及预测:各技术
      • 市场规模及预测:各应用领域
      • 市场规模及预测:各终端用户
    • 墨西哥的循环肿瘤细胞市场
      • 市场规模及预测:各技术
      • 市场规模及预测:各应用领域
      • 市场规模及预测:各终端用户
  • 欧洲
    • 主要的市场趋势与机会
    • 市场规模、预测:各科技
    • 市场规模、预测:各应用领域
    • 市场规模、预测:各终端用户
    • 市场规模、预测:各国
    • 法国循环肿瘤细胞市场
      • 市场规模及预测:各技术
      • 市场规模及预测:各应用领域
      • 市场规模及预测:各终端用户
    • 德国循环肿瘤细胞市场
      • 市场规模及预测:各技术
      • 市场规模及预测:各应用领域
      • 市场规模及预测:各终端用户
    • 义大利循环肿瘤细胞市场
      • 市场规模及预测:各技术
      • 市场规模及预测:各应用领域
      • 市场规模及预测:各终端用户
    • 西班牙循环肿瘤细胞市场
      • 市场规模及预测:各技术
      • 市场规模及预测:各应用领域
      • 市场规模及预测:各终端用户
    • 英国循环肿瘤细胞市场
      • 市场规模及预测:各技术
      • 市场规模及预测:各应用领域
      • 市场规模及预测:各终端用户
    • 其他欧洲的循环肿瘤细胞市场
      • 市场规模及预测:各技术
      • 市场规模及预测:各应用领域
      • 市场规模及预测:各终端用户
  • 亚太地区
    • 主要的市场趋势与机会
    • 亚太地区的市场规模、预测:各科技
    • 亚太地区的市场规模、预测:各应用领域
    • 亚太地区的市场规模、预测:各终端用户
    • 市场规模、预测:各国
    • 中国循环肿瘤细胞市场
      • 市场规模及预测:各技术
      • 市场规模及预测:各应用领域
      • 市场规模及预测:各终端用户
    • 日本循环肿瘤细胞市场
      • 市场规模及预测:各技术
      • 市场规模及预测:各应用领域
      • 市场规模及预测:各终端用户
    • 印度循环肿瘤细胞市场
      • 市场规模及预测:各技术
      • 市场规模及预测:各应用领域
      • 市场规模及预测:各终端用户
    • 韩国循环肿瘤细胞市场
      • 市场规模及预测:各技术
      • 市场规模及预测:各应用领域
      • 市场规模及预测:各终端用户
    • 澳洲循环肿瘤细胞市场
      • 市场规模及预测:各技术
      • 市场规模及预测:各应用领域
      • 市场规模及预测:各终端用户
    • 其他亚太地区的循环肿瘤细胞市场
      • 市场规模及预测:各技术
      • 市场规模及预测:各应用领域
      • 市场规模及预测:各终端用户
  • LAMEA
    • 主要的市场趋势与机会
    • 市场规模、预测:各科技
    • 市场规模、预测:各应用领域
    • 市场规模、预测:各终端用户
    • 市场规模、预测:各国
    • 巴西循环肿瘤细胞市场
      • 市场规模及预测:各技术
      • 市场规模及预测:各应用领域
      • 市场规模及预测:各终端用户
    • 南非循环肿瘤细胞市场
      • 市场规模及预测:各技术
      • 市场规模及预测:各应用领域
      • 市场规模及预测:各终端用户
    • 沙乌地阿拉伯的循环肿瘤细胞市场
      • 市场规模及预测:各技术
      • 市场规模及预测:各应用领域
      • 市场规模及预测:各终端用户
    • UAE循环肿瘤细胞市场
      • 市场规模及预测:各技术
      • 市场规模及预测:各应用领域
      • 市场规模及预测:各终端用户
    • LAMEA的其他地区循环肿瘤细胞市场
      • 市场规模及预测:各技术
      • 市场规模及预测:各应用领域
      • 市场规模及预测:各终端用户

第8章 企业简介

  • Ikonisys Inc.
  • Greiner Bio-One International GmbH
  • Thermo Fisher Scientific
  • SRI International
  • STEMCELL Technologies
  • Miltenyi Biotec
  • Menarini Silicon Biosystems
  • QIAGEN Hannover(QIAGEN)
  • F. Hoffmann-La Roche Ltd.
  • NanoString Technologies, Inc
简介目录
Product Code: A11918

Circulating tumor cell testing enables the detection and quantification of tumor cells in the blood of cancer patients. Different biological phenotypes of CTCs exist: epithelial, mesenchymal, stem cell-like or mixed. They are present in blood in very small quantities, vastly outnumbered by other cells, especially white blood cells. As a result, their detection needs a phase of isolation-enrichment and a second phase of detection. All the recent CTC identification devices combine these two steps (isolation-enrichment and detection) such as ISET, CellSearch System, CTC-chip or EPISPOT. Sometimes, different methods are used in the same device for one step: for instance, the RosetteSep device includes 2 methods of enrichment/isolation: by density and by immunologic separation which is a negative selection. A number of potential applications of circulating tumor cells in prediagnosis, pre-treatment, and intra and post-treatment provide lucrative growth opportunities to players involved in the development of circulating tumor cell (CTC) enrichment and isolation products.

Covid-19 Scenario analysis:

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future owing to the demand for vaccine and treatment drugs for COVID-19. This in turn is expected to have a significant impact on the circulating tumour cell market

Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact analysis:

Increased demand for efficient diagnostic and screening tests and technological advancements in cancer detection is expected to propel the growth of market for CTCs. Several tumor markers that have been introduced in recent years can be used with companion diagnostics to monitor or diagnose a variety of cancers. High adoption of companion diagnostics in monitoring tumor eradication characteristics of cytotoxic drugs is among the few factors propelling the demand in the market for CTCs. Key stakeholders are constantly engaged in endeavours aimed at developing circulating tumor cells based tests, which can prove helpful in the cancer diagnosis. The circulating tumor cell testing is also a useful tool for the development of preventive medicine for cancer. Circulating tumor cell testing can help understand and asses the mechanism of drug during in-vitro experiment in preclinical studies.

Drivers:

Increase in preference for minimum invasive procedure:

Growing demand for minimally invasive diagnostic procedures is anticipated to propel investments by key stakeholders in this area. Circulating tumor cell based liquid biopsy tests lead to limited trauma and enable rapid recovery owing to their non-invasive nature. Moreover, it enables minimal invasive screening of tumors before opting for complex surgical procedures, such as radiotherapy, chemotherapy, and surgical removal of tumors, thus positively impacting the adoption.

Increase in prevalence rate of cancer:

The growing prevalence of cancer is one of the major reasons behind the growth of circulating tumor cell testing market. According to NIH, National Cancer Institute, cancer is one of the major reasons of death globally. According to an estimation from the National Cancer Institute, in 2018 colorectal cancer is projected to contribute around 8.1% of all new cancer cases with estimated deaths around 50,630, which is 8.3% of all cancer deaths caused in the U.S.As reported by the Cancer Research UK, there were 41,804 new cases of colorectal cancer in 2015 and 16,384 deaths due to colon cancer in the U.K. Increase in genetic disorder, alcohol consumption, smoking and lifestyle changes are the major factor behind the rise in cancer cases and also contributing factor for the growth of the circulating tumor cell market.

Key Market players:

  • In March 2018, Biocept Inc received a patent for its Target Selector assays for molecular analysis to improve the patient diagnosis with cancer in China.
  • In May 2021, Natera, a company involved in non-invasive genetic testing and the analysis of circulating cell-free DNA, to present successful results of Signatera, to monitor colorectal cancer and identify disease recurrence.

Key benefits of the report:

  • This study presents the analytical depiction of the global circulating tumor cell industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global circulating tumor cell market share.
  • The current market is quantitatively analyzed from 2021 to 2030 to highlight the global circulating tumor cell market growth scenario.
  • Porter's five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed global circulating tumor cell market analysis based on competitive intensity and how the competition will take shape in coming years.

Questions answered in the Circulating tumor cell Market research report:

  • What are the leading market players active in the circulating tumor cell market?
  • What the current trends will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities in the market?
  • What are the projections for the future that would help in taking further strategic steps?

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Share Analysis/Top Player Positioning
    • 3.4.1. Market Share Analysis/Top Player Positioning 2021
  • 3.5. Market Dynamics
    • 3.5.1. Drivers
    • 3.5.2. Restraints
    • 3.5.3. Opportunities
  • 3.6. COVID-19 Impact Analysis

CHAPTER 4: CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY

  • 4.1. Market Overview
    • 4.1.1. Market Size and Forecast, By Technology
  • 4.2. CTC Detection Enrichment Method
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. CTC Direct Detection Methods
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country
  • 4.4. CTC Analysis
    • 4.4.1. Key Market Trends, Growth Factors and Opportunities
    • 4.4.2. Market Size and Forecast, By Region
    • 4.4.3. Market Share Analysis, By Country

CHAPTER 5: CIRCULATING TUMOR CELL MARKET, BY APPLICATION

  • 5.1. Market Overview
    • 5.1.1. Market Size and Forecast, By Application
  • 5.2. Clinical/Liquid Biopsy
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
    • 5.2.4. Risk Assessment
      • 5.2.4.1. Market Size and Forecast
    • 5.2.4. Screening and Monitoring
      • 5.2.4.1. Market Size and Forecast
  • 5.3. Research
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country
    • 5.3.4. Cancer Stem Cell Tumorigenesis Research
      • 5.3.4.1. Market Size and Forecast
    • 5.3.4. Drug/Therapy Development
      • 5.3.4.1. Market Size and Forecast

CHAPTER 6: CIRCULATING TUMOR CELL MARKET, BY END USERS

  • 6.1. Market Overview
    • 6.1.1. Market Size and Forecast, By End Users
  • 6.2. Hospital Clinics
    • 6.2.1. Key Market Trends, Growth Factors and Opportunities
    • 6.2.2. Market Size and Forecast, By Region
    • 6.2.3. Market Share Analysis, By Country
  • 6.3. Research Academic Institutes
    • 6.3.1. Key Market Trends, Growth Factors and Opportunities
    • 6.3.2. Market Size and Forecast, By Region
    • 6.3.3. Market Share Analysis, By Country
  • 6.4. Diagnostic Centres
    • 6.4.1. Key Market Trends, Growth Factors and Opportunities
    • 6.4.2. Market Size and Forecast, By Region
    • 6.4.3. Market Share Analysis, By Country

CHAPTER 7: CIRCULATING TUMOR CELL MARKET, BY REGION

  • 7.1. Market Overview
    • 7.1.1. Market Size and Forecast, By Region
  • 7.2. North America
    • 7.2.1. Key Market Trends and Opportunities
    • 7.2.2. Market Size and Forecast, By Technology
    • 7.2.3. Market Size and Forecast, By Application
    • 7.2.4. Market Size and Forecast, By End Users
    • 7.2.5. Market Size and Forecast, By Country
    • 7.2.6. U.S. Circulating Tumor Cell Market
      • 7.2.6.1. Market Size and Forecast, By Technology
      • 7.2.6.2. Market Size and Forecast, By Application
      • 7.2.6.3. Market Size and Forecast, By End Users
    • 7.2.7. Canada Circulating Tumor Cell Market
      • 7.2.7.1. Market Size and Forecast, By Technology
      • 7.2.7.2. Market Size and Forecast, By Application
      • 7.2.7.3. Market Size and Forecast, By End Users
    • 7.2.8. Mexico Circulating Tumor Cell Market
      • 7.2.8.1. Market Size and Forecast, By Technology
      • 7.2.8.2. Market Size and Forecast, By Application
      • 7.2.8.3. Market Size and Forecast, By End Users
  • 7.3. Europe
    • 7.3.1. Key Market Trends and Opportunities
    • 7.3.2. Market Size and Forecast, By Technology
    • 7.3.3. Market Size and Forecast, By Application
    • 7.3.4. Market Size and Forecast, By End Users
    • 7.3.5. Market Size and Forecast, By Country
    • 7.3.6. France Circulating Tumor Cell Market
      • 7.3.6.1. Market Size and Forecast, By Technology
      • 7.3.6.2. Market Size and Forecast, By Application
      • 7.3.6.3. Market Size and Forecast, By End Users
    • 7.3.7. Germany Circulating Tumor Cell Market
      • 7.3.7.1. Market Size and Forecast, By Technology
      • 7.3.7.2. Market Size and Forecast, By Application
      • 7.3.7.3. Market Size and Forecast, By End Users
    • 7.3.8. Italy Circulating Tumor Cell Market
      • 7.3.8.1. Market Size and Forecast, By Technology
      • 7.3.8.2. Market Size and Forecast, By Application
      • 7.3.8.3. Market Size and Forecast, By End Users
    • 7.3.9. Spain Circulating Tumor Cell Market
      • 7.3.9.1. Market Size and Forecast, By Technology
      • 7.3.9.2. Market Size and Forecast, By Application
      • 7.3.9.3. Market Size and Forecast, By End Users
    • 7.3.10. UK Circulating Tumor Cell Market
      • 7.3.10.1. Market Size and Forecast, By Technology
      • 7.3.10.2. Market Size and Forecast, By Application
      • 7.3.10.3. Market Size and Forecast, By End Users
    • 7.3.11. Rest Of Europe Circulating Tumor Cell Market
      • 7.3.11.1. Market Size and Forecast, By Technology
      • 7.3.11.2. Market Size and Forecast, By Application
      • 7.3.11.3. Market Size and Forecast, By End Users
  • 7.4. Asia-Pacific
    • 7.4.1. Key Market Trends and Opportunities
    • 7.4.2. Market Size and Forecast, By Technology
    • 7.4.3. Market Size and Forecast, By Application
    • 7.4.4. Market Size and Forecast, By End Users
    • 7.4.5. Market Size and Forecast, By Country
    • 7.4.6. China Circulating Tumor Cell Market
      • 7.4.6.1. Market Size and Forecast, By Technology
      • 7.4.6.2. Market Size and Forecast, By Application
      • 7.4.6.3. Market Size and Forecast, By End Users
    • 7.4.7. Japan Circulating Tumor Cell Market
      • 7.4.7.1. Market Size and Forecast, By Technology
      • 7.4.7.2. Market Size and Forecast, By Application
      • 7.4.7.3. Market Size and Forecast, By End Users
    • 7.4.8. India Circulating Tumor Cell Market
      • 7.4.8.1. Market Size and Forecast, By Technology
      • 7.4.8.2. Market Size and Forecast, By Application
      • 7.4.8.3. Market Size and Forecast, By End Users
    • 7.4.9. South Korea Circulating Tumor Cell Market
      • 7.4.9.1. Market Size and Forecast, By Technology
      • 7.4.9.2. Market Size and Forecast, By Application
      • 7.4.9.3. Market Size and Forecast, By End Users
    • 7.4.10. Australia Circulating Tumor Cell Market
      • 7.4.10.1. Market Size and Forecast, By Technology
      • 7.4.10.2. Market Size and Forecast, By Application
      • 7.4.10.3. Market Size and Forecast, By End Users
    • 7.4.11. Rest of Asia Pacific Circulating Tumor Cell Market
      • 7.4.11.1. Market Size and Forecast, By Technology
      • 7.4.11.2. Market Size and Forecast, By Application
      • 7.4.11.3. Market Size and Forecast, By End Users
  • 7.5. LAMEA
    • 7.5.1. Key Market Trends and Opportunities
    • 7.5.2. Market Size and Forecast, By Technology
    • 7.5.3. Market Size and Forecast, By Application
    • 7.5.4. Market Size and Forecast, By End Users
    • 7.5.5. Market Size and Forecast, By Country
    • 7.5.6. Brazil Circulating Tumor Cell Market
      • 7.5.6.1. Market Size and Forecast, By Technology
      • 7.5.6.2. Market Size and Forecast, By Application
      • 7.5.6.3. Market Size and Forecast, By End Users
    • 7.5.7. South Africa Circulating Tumor Cell Market
      • 7.5.7.1. Market Size and Forecast, By Technology
      • 7.5.7.2. Market Size and Forecast, By Application
      • 7.5.7.3. Market Size and Forecast, By End Users
    • 7.5.8. Saudi Arabia Circulating Tumor Cell Market
      • 7.5.8.1. Market Size and Forecast, By Technology
      • 7.5.8.2. Market Size and Forecast, By Application
      • 7.5.8.3. Market Size and Forecast, By End Users
    • 7.5.9. UAE Circulating Tumor Cell Market
      • 7.5.9.1. Market Size and Forecast, By Technology
      • 7.5.9.2. Market Size and Forecast, By Application
      • 7.5.9.3. Market Size and Forecast, By End Users
    • 7.5.10. Rest of LAMEA Circulating Tumor Cell Market
      • 7.5.10.1. Market Size and Forecast, By Technology
      • 7.5.10.2. Market Size and Forecast, By Application
      • 7.5.10.3. Market Size and Forecast, By End Users

CHAPTER 8: COMPANY PROFILES

  • 8.1. Ikonisys Inc.
    • 8.1.1. Company Overview
    • 8.1.2. Key Executives
    • 8.1.3. Company Snapshot
    • 8.1.4. Operating Business Segments
    • 8.1.5. Product Portfolio
    • 8.1.6. Business Performance
    • 8.1.7. Key Strategic Moves and Developments
  • 8.2. Greiner Bio-One International GmbH
    • 8.2.1. Company Overview
    • 8.2.2. Key Executives
    • 8.2.3. Company Snapshot
    • 8.2.4. Operating Business Segments
    • 8.2.5. Product Portfolio
    • 8.2.6. Business Performance
    • 8.2.7. Key Strategic Moves and Developments
  • 8.3. Thermo Fisher Scientific
    • 8.3.1. Company Overview
    • 8.3.2. Key Executives
    • 8.3.3. Company Snapshot
    • 8.3.4. Operating Business Segments
    • 8.3.5. Product Portfolio
    • 8.3.6. Business Performance
    • 8.3.7. Key Strategic Moves and Developments
  • 8.4. SRI International
    • 8.4.1. Company Overview
    • 8.4.2. Key Executives
    • 8.4.3. Company Snapshot
    • 8.4.4. Operating Business Segments
    • 8.4.5. Product Portfolio
    • 8.4.6. Business Performance
    • 8.4.7. Key Strategic Moves and Developments
  • 8.5. STEMCELL Technologies
    • 8.5.1. Company Overview
    • 8.5.2. Key Executives
    • 8.5.3. Company Snapshot
    • 8.5.4. Operating Business Segments
    • 8.5.5. Product Portfolio
    • 8.5.6. Business Performance
    • 8.5.7. Key Strategic Moves and Developments
  • 8.6. Miltenyi Biotec
    • 8.6.1. Company Overview
    • 8.6.2. Key Executives
    • 8.6.3. Company Snapshot
    • 8.6.4. Operating Business Segments
    • 8.6.5. Product Portfolio
    • 8.6.6. Business Performance
    • 8.6.7. Key Strategic Moves and Developments
  • 8.7. Menarini Silicon Biosystems
    • 8.7.1. Company Overview
    • 8.7.2. Key Executives
    • 8.7.3. Company Snapshot
    • 8.7.4. Operating Business Segments
    • 8.7.5. Product Portfolio
    • 8.7.6. Business Performance
    • 8.7.7. Key Strategic Moves and Developments
  • 8.8. QIAGEN Hannover (QIAGEN)
    • 8.8.1. Company Overview
    • 8.8.2. Key Executives
    • 8.8.3. Company Snapshot
    • 8.8.4. Operating Business Segments
    • 8.8.5. Product Portfolio
    • 8.8.6. Business Performance
    • 8.8.7. Key Strategic Moves and Developments
  • 8.9. F. Hoffmann-La Roche Ltd.
    • 8.9.1. Company Overview
    • 8.9.2. Key Executives
    • 8.9.3. Company Snapshot
    • 8.9.4. Operating Business Segments
    • 8.9.5. Product Portfolio
    • 8.9.6. Business Performance
    • 8.9.7. Key Strategic Moves and Developments
  • 8.10. NanoString Technologies, Inc
    • 8.10.1. Company Overview
    • 8.10.2. Key Executives
    • 8.10.3. Company Snapshot
    • 8.10.4. Operating Business Segments
    • 8.10.5. Product Portfolio
    • 8.10.6. Business Performance
    • 8.10.7. Key Strategic Moves and Development